Navigation Links
Ontak in Medical Technology

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

...cal trial to confirm the clinical effectiveness of ontak in certain patients with cutaneous T-cell lymphoma (CTCL). ontak is indicated for the treatment of patients with pe...t of the IL-2 receptor. The safety and efficacy of ontak in patients with CTCL whose malignant cells do not...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

... with cutaneous T-cell lymphoma (CTCL) showed that ontak was more than twice as effective as placebo in eli...American Society of Clinical Oncology (ASCO). ontak is indicated for the treatment of patients with pe...onent of the IL-2 receptor have not been examined. ontak was granted accelerated approval in February 1999....
Ontak in other areas

Ontak (Denileukin Diftitox) Drug Information: Uses, Side Effects, Drug ...

Learn about the prescription medication Ontak (Denileukin Diftitox), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.

ONTAK

ONTAK is supplied in single use vials as a sterile, frozen solution intended for ... Each 2 mL vial of ONTAK contains 300 mcg of ...

Ontak, Denileukin Diftitox - Chemotherapy Drugs, Chemo Drug Side Effects

Ontak is the trade name for Denileukin Diftitox. Ontak is a targeted therapy. ... professionals may use the trade name Ontak when referring to the generic drug ...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) To Full ...

... priority review a supplemental biologics license application (sBLA) for ONTAK(R) ... ONTAK is indicated for the treatment of patients with persistent or recurrent ...

ONTAK(R) (denileukin Diftitox) Achieves 49.1% Overall Response Rate In ...

Preliminary results of the largest randomized, placebo-controlled clinical trial ever conducted in patients with cutaneous T-cell lymphoma (CTCL) showed that ONTAK ...

Success Story: Ontak (NSC 697979)

1998 Ontak (NSC 697979), also known as denileukin diftitox or interleukin-2 (IL ... Ontak is one of four NCDDG-developed agents approved by the FDA since the ...
Other Tags
(Date:7/14/2014)... (PRWEB) July 14, 2014 The ... in Hicksville and Hauppauge, NY, has announced the ... long-lasting treatment for diabetic macular edema (DME) patients. ... an additional FDA-approved indication for use in diabetic ... FDA in 2009 for treatment of retinal vascular ...
(Date:7/14/2014)... 2014 There’s an old adage that says ... Lash Palette say the products offered in their preorder ... “You can reserve The Lash Palette for $40,” said Jenelle ... . , Paris explained that the first 1,000 have already ... , She went on to point out that her company ...
(Date:7/14/2014)... works could lead to the next generation of treatments ... forms when recently evolved genes are damaged, and cells ... , Astrobiologists Dr Charley Lineweaver from The Australian ... University teamed up with oncologist Dr Mark Vincent from ... model. , "The rapid proliferation of cancer cells ...
(Date:7/14/2014)... According to a new market research ... SiC, and Others), Devices (Power IC, Power Module & ... to 2014 - 2020", the Power Electronics market is ... electronics market is valued at $36.86 Billion and expected ... 2020. The report also includes an in-depth analysis of ...
(Date:7/14/2014)... may buffer some of the adverse health effects of ... researchers from the American Cancer Society, The Cooper Institute, ... the journal Mayo Clinic Proceeding s, and finds ... blood markers associated with cardiovascular disease is markedly less ... has been linked to an increase risk of obesity, ...
Breaking Medicine News(10 mins):Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3Health News:The Lash Palette Preorder Event Has Officially Begun 2Health News:New theory turns cancer on its head 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 3Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 4Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 5Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
Other Contents